FY2024 Earnings Forecast for IN8bio Issued By HC Wainwright

IN8bio, Inc. (NASDAQ:INAB) – Equities research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of IN8bio in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth expects that the company will earn ($0.59) per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.52) per share. HC Wainwright also issued estimates for IN8bio’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.17) EPS and FY2028 earnings at $0.54 EPS.

IN8bio Stock Up 6.1 %

Shares of NASDAQ INAB opened at $0.34 on Friday. IN8bio has a one year low of $0.22 and a one year high of $2.48. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.66 and a current ratio of 1.84. The business has a fifty day simple moving average of $0.30 and a 200 day simple moving average of $0.68.

Institutional Trading of IN8bio

An institutional investor recently raised its position in IN8bio stock. Sigma Planning Corp lifted its stake in IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 851,280 shares of the company’s stock after buying an additional 251,600 shares during the period. Sigma Planning Corp owned about 1.82% of IN8bio worth $230,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.